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The SARS-CoV-2 pandemic has spread to all parts of the world and can cause life-
threatening pneumonia and other severe disease manifestations known as COVID-19.
This health crisis has resulted in a significant effort to stop the spread of this new
coronavirus. However, while propagating itself in the human population, the virus
accumulates mutations and generates new variants with increased fitness and the
ability to escape the human immune response. Here we describe a color-based
barcoded spike flow cytometric assay (BSFA) that is particularly useful to evaluate and
directly compare the humoral immune response directed against either wild type (WT) or
mutant spike (S) proteins or the receptor-binding domains (RBD) of SARS-CoV-2. This
assay employs the human B lymphoma cell line Ramos, transfected for stable expression
of WT or mutant S proteins or a chimeric RBD-CD8 fusion protein. We find that the alpha
and beta mutants are more stably expressed than the WT S protein on the Ramos B cell
surface and/or bind with higher affinity to the viral entry receptor ACE2. However, we find a
reduce expression of the chimeric RBD-CD8 carrying the point mutation N501Y and
E484K characteristic for the alpha and beta variant, respectively. The comparison of the
humoral immune response of 12 vaccinated probands with 12 COVID-19 patients shows
that after the boost, the S-specific IgG class immune response in the vaccinated group is
similar to that of the patient group. However, in comparison to WT the specific IgG serum
antibodies bind less well to the alpha variant and only poorly to the beta variant S protein.
This is in line with the notion that the beta variant is an immune escape variant of SARS-
CoV-2. The IgA class immune response was more variable than the IgG response andorg September 2021 | Volume 12 | Article 7307661
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Frontiers in Immunology | www.frontiersin.higher in the COVID-19 patients than in the vaccinated group. In summary, we think that
our BSFA represents a useful tool to evaluate the humoral immunity against emerging
variants of SARS-CoV-2 and to analyze new vaccination protocols against these variants.Keywords: COVID-19, coronavirus, SARS-CoV-2, virus variants, spike protein, RBD, humoral immunity,
flow cytometryINTRODUCTION
Since December 2019, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV2) has been spreading in the human
population as a pathogen causing the coronavirus disease 2019
(COVID-19) associated with severe pneumonia (1). The rapid
spread of this pandemic virus and the severity of this worldwide
health crisis is associated with three features (2). First, SARS-CoV-
2 is a new member of the beta-coronavirus family and hence there
is no human immunity against this emerging virus (3). Second,
SARS-CoV-2 enters the cells via the angiotensin-converting
enzyme 2 (ACE2), a receptor widely expressed in human
mucosal tissues of the nose and mouth and particularly
abundant in the lung (4, 5). Third, SARS-CoV-2 is a positive-
strand RNA virus and can thus rapidly generate mutations (6).
The virus binds to the ACE2 entry receptor via the trimeric spike
(S) protein prominently expressed on the viral membrane (7).
Upon binding to ACE2, the S protein undergoes a conformational
change. It is cleaved by cellular proteases into an S1 and S2
portion, with the latter inducing a fusion reaction between the viral
and cellular membrane, thereby starting the infection cycle (8).
The RBD, that directly binds to ACE2 is located within the S1
portion. The structure of the SARS-CoV-2 trimeric S protein has
been determined by cryo-electron microscopy at the atomic level.
It has revealed that the RBD can assume a closed (down) or open
(up) conformation, with only the latter being able to interact with
the ACE2 entry receptor (9).
The trimeric S protein of SARS-CoV-2 is a prominent target
of the humoral immune response (9–11). In particular, RBD-
specific antibodies can inhibit the binding of the S protein to
ACE2 and thus function as neutralizing antibodies that block
viral entry into the target cells (4). Indeed, it has been found that
the RBD is an immunodominat structure of the S protein and
targeted by more than 90% of the neutralizing antibodies (12).
Several specific monoclonal antibodies (mAb) have been
generated and are used in the clinic as therapeutic reagents to
treat acute COVID-19. These mAb can be directed to the full-
length S protein or the RBD domain. A co-crystallization of Fab
fragments of anti-RBD mAb with the RBD resulted in their
classification in ACE2-blocking or non-blocking antibodies
(9, 12). The S protein or its encoding mRNA are used for the
rapid development of vaccines that counteract the spread of the
SARS-CoV-2. In particular, mRNA vaccines could be rapidly
produced and play an essential role in the worldwide vaccination
programs counteracting the spread of the virus. However, these
efforts may be compromised by the appearance of SARS-CoV-2
variants that start to spread in different parts of the world (6).org 2The SARS-CoV-2 variants carry characteristic mutations in the
RBD and other parts of the S protein. According to the World
Health Organization’s recommendations (WHO), they are now
classified as Greek letters (13). They are usually characterized by
their increased infectivity, their ability to multiply more rapidly
in an infected host and to escape recognition by at least some
neutralizing antibodies generated against the S protein of WT
SARS-CoV-2. Hence, the virus variants represent “fitness” and/
or “immune evasion” mutants (14).
Many S protein-based serological assays have been developed
to evaluate the success of the diverse vaccination programs and
determine the anti-SARS-CoV-2 humoral immune status of a
human population. These are based on linear peptides or the full-
length S protein and frequently use the ELISA technique (15).
Recently also flow cytometric techniques have been introduced
(16–18). The advantage of these assays is that they use cells
expressing native S proteins with the same orientation and a
glycosylation pattern similar to that found on the viral
membrane. This also applies to a cell-based enzyme-linked
immunosorbent assay used for the detection of a HIV or
SARS-CoV-2 infection (19, 20). Here we describe a flow
cytometric assay that allows comparison of the humoral
immune response of vaccinated and infected persons in terms
of its reactivity towards the S protein and RBD of either WT or
the variants of SARS-CoV-2.MATERIALS AND METHODS
Participants
Four female and eight male COVID-19 patients (n=12) with mean
ages of 65 and 62 years were recruited at the Medical Center
University of Freiburg. Written informed consent was obtained
from all participants in this study. Convalescent plasma was
collected according to the FDA recommendation. Donors met
routine FDA-established blood donor eligibility requirements and
had previous SARS-CoV-2 infection documented by laboratory
testing for the virus during illness or antibodies to the virus after
recovery from suspected illness. In addition, six female and six
male subjects (n=12) vaccinated with BioNTech/Pfizer Comirnaty
were recruited with a mean age of 49.33 and 44.83 years,
respectively at the Medical Center – University of Freiburg.
Written informed consent was obtained from all participants.
The study was approved by the Ethical Committee of the
University of Freiburg (EK-Freiburg no 315/10). Serum and
plasma samples were aliquoted and stored at−80°C.September 2021 | Volume 12 | Article 730766
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The retroviral expression vectors encoding the WT, alpha or beta
variant S protein of SARS-CoV-2 are based on the pMIG vector
backbone (pMIG was a gift from William Hahn [Addgene
plasmid # 9044; http://n2t.net/addgene:9044; RRID:
Addgene_9044)]. The cDNA of the relevant S protein genes
was amplified by PCR with primers containing the proper
extensions to be ligated into the linearized pMIG vector by a
Gibson assembly-like method, namely the In-Fusion cloning
protocol from ClonTech. To connect the PCR fragments, we
designed them so that they have a 15 base pair overlap. The
cDNA encoding the WT S protein is derived from the plasmid
pVAX1-SARS2-S with a codon-optimized sequence of the S
protein gene of SARS-CoV-2 (21). The alpha and beta S
protein cDNA were synthesized in ITD gBlocks. The retroviral
expression vector encoding the RBD-CD8 chimeric const ruct is
based on the pMIG-CD8 vector containing the murine CD8 gene
cDNA. The cDNA encoding the RBD of the WT S protein was
amplified by PCR and ligated into the linearized pMIG-CD8
vector so that the RBD was placed in between the leader peptide
and the extracellular Ig domain of CD8. The point mutations in
the RBD-CD8 construct were generated by site-directed
mutagenesis. For the design of primers and plasmids, we used
Geneious 9.0.5 software. The component mixture used for the
PCR and the PCR program was set up according to CloneAmp
HIFI PCR Premix. All generated vectors were sequenced
(Eurofins Genomics) and the sequencing results were analyzed
by Geneious software
Cell Culture
Ramos B cells were cultured in RPMI medium supplemented
with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin
and 0.12% b-mercaptoethanol (RPMI+). The Ramos B cell
cultures were split every 2 days.
Retroviral Production in Phoenix Cells and
Transduction of Ramos B Cells
Phoenix cells were cultured in iscove basal medium (IBM)
supplemented with 10% FBS and 1% penicillin streptomycin
(IBM+). Cells were split every 2 days by diluting them 1/10.
One day before the transfection with the retrovirus producing
plasmids pKAT and pMIG, 5x105 Phoenix cells at 70 % confluency
were pipetted into a coated 6-well plate. Afterward, the cells were
supplemented with 2 ml of IBM+. Between 18 and 24 hours later,
the transfection was performed on cells at 70% confluency, using
Polyjet transfection reagent, according to the manufacturer’s
instructions. After 2 days of culture, the virus-containing
supernatant was collected and filtered through a 0.45 µm filter.
Afterward, Polybrene was added at a concentration of 1 µl/ml.
Ramos-null B cells were split the day before the transduction, 6x105
Ramos-null cells were resuspended in 1 ml of the transduction
mixture and then centrifuged for 3 h at 400xg and 37°C. After this
step, the viral supernatant was replaced with RPMI+. The cells were
then transferred to a 12-well plate in a total volume of 2.5 ml
of medium.Frontiers in Immunology | www.frontiersin.org 3Barcoding
For barcoding, 106 Ramos B cells were resuspenden in 1 ml of
DPBS alone or with different concentrations of the cell
proliferation tracer CytoTell blue (1:250, 1:1250, 1:10.000). The
cells were incubated for 30 min in the dark at room temperature,
washed twice with DPBS and then combined in one test tube for
further staining.Cell Surface Staining and Subsequent
Analysis
The following flow cytometry antibodies were obtained from
BioLegend: anti human IgG (M1310G05), anti human IgA
(HP6123), anti mouse CD8 (53-6.7), anti mouse kappa light
chain (RMK-12). For primary staining, barcoded cells were
incubated with the binding reagent for 30 min at 4 °C in the
dark. After incubation, the cells were washed twice with DPBS.
Secondary staining was performed under the same conditions
using appropriate fluorescent label secondary antibodies. The
cells were washed resuspended in DPBS for FACS analysis on a
ThermoFisher Attune NxT flow cytometer. Filters used 440/50,
530/30, 585/16 and 670/14. Flow cytometry data were analyzed
with FlowJo v10 (Tristart). The mean fluorescent intensity (MFI)
values from each cell line were then normalized to the MFI from
the control Null cell line within each barcoded sample, and the
resulting normalized MFI was used for comparison of binding to
different Spikes or RBDs variants.ACE-Ig Reagent and mAb
ACE2-Ig was cloned by fusing the human ACE2 Q18-V739
fragment to the human IgG1-Fc portion (E99-K330 portion,
where 1st amino acid is G encoded by J-CH1 fusion) of the
expression vector from Oxford Genetics (pSF-CMV-HuIgG1).
Cloning constructs were used to transfect FreeStyle 293-F cells
that were grown in suspension using FreeStyle 293 expression
medium (Life Technologies) at 37°C in a humidified 8% CO2
incubator rotating at 125 rpm. Cells were grown to a density of
2.5 million cells per mL, transfected using PEI (4 µg/mL in cell
suspension) and DNA (1200 ng/ml in cell suspension), and
cultivated for 3 days. The supernatants were harvested and
ACE2-Ig was purified by protein G SpinTrap columns
according to manufacturer’s instructions (Cytiva, 28903134).
The isolation of monoclonal TRES antibodies is described in
(22). Briefly, TRIANNI C57/Bl6 mouse line HHKKLL (Patent
US 2013/0219535 A1) was primed with a plasmid encoding
wild type SARS-COV-2 spike protein and boosted twice
intramuscularly with stabilized trimeric S protein of SARS-
CoV-2 adjuvanted with Monophosphoryl Lipid A (MPLA)
liposomes (Polymun Scientific GmbH, Klosterneuburg,
Austria). Spleen cells were fused with Sp2/0 cells, and
hybridoma clones were screened for spike-binding antibodies
with a flow-based assay as described by (17). Positive clones were
subcloned by the limiting dilution method. Rearranged VH and
VL exons were cloned by the 5’ Race method and sequenced.September 2021 | Volume 12 | Article 730766
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Sera of vaccinated persons, diluted 1/100, were tested for anti-
spike IgG antibodies by ELISA, using the EI 2601-9601 G SARS-
CoV-2 Spike IgG kit from Euroimmun applying the reagents and
the protocol provided by the manufacturer. The CE certified
assay is widely used to determine the presence of SARC-COV-2
specific antibodies (23). According to the manufacturer, the
assay’s sensitivity is 94,4% and the specificity 99.8%RESULTS
Setting Up the Spike Flow
Cytometric Assay
The human Burkitt lymphoma cell line Ramos is a valuale tool of
immunological research (24). These cells can be propagated
efficiently in cell cultures and modified by the CRISPR/Cas9
technique (25). In our study, we used a Ramos-null line lacking
all four components of the B cell antigen receptor (BCR), namely
heavy chain, light chain, Iga and Igb (26). Although the Ramos-
null cells grow more slowly than Ramos wild type (WT), they can
be maintained in culture and expanded to large cell numbers.
Furthermore, the Ramos-null cells also carry on their surface a
receptor for ecotropic retroviruses (ecoR) that allows the efficient
transduction of these cells with murine retroviral vectors
(Figure 1A). For the expression of different S constructs on the
surface of Ramos-null cells, we used a pMIG vector carrying after
the LTR promoter the construct sequence, an internal ribosome
entry site (IRES) and the sequence coding for the green
fluorescent protein (GFP) (Figure 1B). This vector systemFrontiers in Immunology | www.frontiersin.org 4allows us to detect and enrich the transduced (GFP-positive)
Ramos-null cells and correlate to some extent the expression of
the S protein with that of GFP. The different retroviral vectors
were used to express either the S protein of SARS-CoV-2 or a
chimeric protein carrying the isolated RBD of the S protein in
front of the murine CD8 molecule.
Furthermore, we also expressed the S protein of two SARS-
CoV-2 mutants, namely the alpha variant (B1.1.7) and the beta
variant (B.1.351) (Figure 1C). These mutant S proteins differ
from the WT SARS-CoV-2 sequence at 8-10 amino-acid
positions (Figure 1D). In the RBD sequence, the mutant S
proteins carry critical amino acid exchange mutations that
influence the binding of the S protein to the ACE2 target and
its detection by neutralizing antibodies (6, 27). These are an
asparagine to tyrosine exchange (N501Y) in the alpha variant
and the same mutation in combination with a glutamate to lysine
(E484K) exchange mutation in the beta variant. In addition, the S
proteins expressed on the Ramos cell surface carry a deletion of
four amino acids (RRAR) at the border between the S1 and S2
domains, preventing their cleavage by cellular proteases.
To directly compare Ramos cells expressing different S
protein constructs in their binding of either a soluble ACE2 or
anti-SARS-CoV-2 antibodies, we developed a color-based
barcoded spike protein flow cytometric assay (BSFA). To this
end, we first incubated Ramos cells with PBS alone or with
different concentrations of the cell proliferation tracer CytoTell
blue. The Ramos cells are then washed and combined in one
sample tube (Figure 2A) before being stained with different
binding reagents. Finally, the combined Ramos cells are




FIGURE 1 | Expression system for the generation of Ramos-null B cells carrying on their surface WT or variant spike proteins of SARS-CoV-2. (A) Generation of the
Ramos-null cells lacking functional genes for the four components (heavy chain, light chain, Iga, Igb) of the IgM-BCR by the CRISPR/Cas9 technique. These cells
also carry the ecoR receptor for efficient retroviral transfection. (B) Retroviral vector used for the linked expression of the spike protein and GFP using an internal
ribosome entry site (IRES) sequence in front of the GFP cDNA. (C) Schematic drawing of the expressed S proteins with the WT (green), the receptor binding domain
(RBD) (orange) attached to the murine CD8 protein (grey), the alpha variant B.1.1.7 (blue) and the beta variant B.1.3.5.1 (red). (D) Location of the amino acid
exchange or deletion mutations in the S1 and S2 domain of the S protein. Alterations in the S protein of the alpha variant are indicated in blue and those of the beta
variant in red.September 2021 | Volume 12 | Article 730766
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the different S constructs, we used an ACE2-immunoglobulin
(ACE2-Ig) chimeric protein carrying at the C-terminus instead
of the TM region of ACE2 the CH2 and CH3 domains of human
IgG1 (Figure 2C). The different Ramos cells were first incubated
with increasing concentrations of ACE2-Ig, washed, stained with
allophycocyanin (APC)-coupled anti-human IgG antibodies and
then analyzed for APC and GFP fluorescence by flow cytometry
(Figure 2D). We found that Ramos cells expressing the RBD-
CD8 construct show the most robust ACE2-Ig binding. This is in
line with a structural analysis showing that only a minority of the
trimeric S proteins display the RBD in an open (ACE2-binding)
conformation (9, 28), whereas as part of the RBD-CD8 construct,
the RBD should be fully accessible for ACE2 binding. The
directed comparison of Ramos cells expressing the WT S
constructs or the alpha and beta variants shows that the
variants display a stronger ACE2-Ig binding (Figure 2D). This
is particularly visible at the lower (6 ug/ml) concentration of
ACE2-Ig and confirmed by a more detailed titration experiment
(Figure 2E). These data show that the BSFA can be used to
evaluate the expression and binding activity of WT and mutant
SARS-CoV-2 S proteins to ACE2.
Evaluation of Anti-S Antibodies and Sera
We next incubated the four different Ramos cell lines with 1 ug/
ml of monoclonal antibodies (mAb) generated against the WT
trimeric S protein of SARS-CoV-2. These TRIANNI-Erlangen
anti-SARS-CoV-2- Spike (TRES) mAb are either directed against
the hACE2 binding site (TRES224, TRES6) or the N-terminalFrontiers in Immunology | www.frontiersin.org 5domain (TRES328) of the S protein (22). The BSFA showed that
the TRES224 and TRES6 antibodies are indeed directed against
the RBD of the S protein whereas TRES328 hardly binds this
structure (Figure 3A). A strong RBD binding was also found
when using the therapeutic anti-SARS-Cov-2 antibody R10987
characterized as a class 3 RBD binder (9). The RBD-specific mAb
TRES224, TRES6 and R10987 also bind well to the alpha and
beta variant S proteins, which is not true for TRES328.
Interestingly, the titration of the three RBD-specific mAb
shows that they bind even better to Ramos cells expressing the
variant than those expressing the WT S proteins (Figure 3B).
These data demonstrate that on the Ramos cell surface the
variant S proteins are expressed as well as or even better than
the WT S protein and that the BSFA can be used to evaluate the
fine specificity of anti-SARS-CoV-2 antibody response.
Having demonstrated that the BSFA works well in the
evaluation and characterization of anti-S antibodies, we next
analyzed sera from 12 persons (V1-V12) who had been
vaccinated with the BioNTech/Pfizer mRNA vaccine
(Comirnaty®). For each person, we obtained sera before or
shortly after vaccination, 10-14 days after the first and 10-15
days after the second vaccination (Table 1). As an example, for
the human humoral response after vaccination, we show a BSFA
study for S-specific IgG and IgA antibodies in the sera of a 47-
year-old female (V7) taken either 1 day before or 12 days after
the first and 10 days after the secondary (boost) vaccination
(Figure 4). No S-specific antibodies were found before
immunization, and that was the case for all analyzed sera
(Supplementary Figure 1). After the first vaccination,A B
D E
C
FIGURE 2 | Establishment of the color-based barcoded spike flow assay (BSFA). (A) Labeling of four different Ramos cell populations by exposure to different
concentrations (0, 1:250, 1:1250, 1:10.000) of CytoTell blue for further analysis in one test tube. (B) Gating strategy for the analysis of four different Ramos cell
populations by flow cytometry. The CytoTell blue -loaded Ramos cells are separated by the blue fluorescent protein (BFP) gate. (C) Structural model of the chimeric
ACE2-Ig molecule used for the detection of the S protein or the RBD-CD8 chimera on transfected Ramos cells. (D) Analysis of Ramos cells expressing the WT
(green), alpha variant (blue), beta variant (red) S protein or the RBD-CD8 construct (orange). The cells were exposed to either 50 or 6 ug/ml of ACE2-Ig, washed,
stained with APC-coupled anti-human IgG antibodies and then analyzed by flow cytometry. Shown is the dot plot depicting the GFP and APC fluorescence form
each one of the variants overlay with the Ramos-Null (GFP-) control cell line. (E) Titration of the ACE2-Ig binding to the four indicated Ramos cell populations. As
negative control we used Ramos cells without S protein (black). The mean values of three different experiments are shown.September 2021 | Volume 12 | Article 730766
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against the WT and RBD-CD8 but not against the alpha and
beta variant S proteins. The primary IgA antibody response of V7
is also predominantly directed towards the WT but not the
variant S proteins. After the secondary immunization, the
amount of IgG antibodies directed against the WT S protein
and RBD has increased. The sera now also contain IgG
antibodies binding to the alpha and beta variant S proteins.
However, in contrast to the previously tested mAb, the serum
antibodies of V7 recognize theWT better than the alpha and beta
variants’ S proteins. (Figure 4, outer right panel). The secondaryFrontiers in Immunology | www.frontiersin.org 6IgA antibody response did not improve much compared to the
primary response. Only a few IgA antibodies bound to the
Ramos cells expressing high amounts of the alpha and beta
variants’ S proteins.
The analysis of sera from all 12 vaccinated persons confirms
these findings (Figures 5A, B). The S-specific IgG antibody
response is in most cases higher in the secondary than in the
primary sera. The secondary sera also contain IgG antibodies
against the alpha and beta variants S proteins, albeit at a lower
level. This is in line with a study showing that the protective
antibody respose of mRNA vaccinated person is sufficient but
lower in the case of the alpha mutant (29). Four of the 12
vaccinated persons (V1, V2, V4 and V10) already had a high
anti-S primary IgG response that did not improve substantially
after the secondary immunization. The S-specific IgA antibody
response is more variable from person to person and is not
always improved in the secondary response. Most sera of the
vaccinated group had IgA antibodies that bind more strongly to
Ramos cells expressing the WT than those expressing the alpha
and beta variants’ S proteins. For comparison we also studied the
blood samples of the 12 vaccinated persons with an ELISA
detecting IgG antibodies directed against the S1 part of the
WT S protein (Supplementary Figure 2). This assay also
shows that in most cases the IgG antibody response is higher
in the secondary than in the primary response. However, there
are some discrepancies in the variability of the primary response
and the secondary response of V7 that may be due to the
detection of different epitopes on the isolated S1 part of theA B
FIGURE 3 | BSFA study of the binding of four monoclonal antibodies (mAb) to S protein- expressing Ramos cells. (A) Ramos cells carrying the WT (green), alpha
variant (blue), beta variant (red) S protein or the RBD-CD8 construct (orange) cells were incubated with 1 ug/ml of the mAb TRES224, TRES6, TRES328 and R10987.
After washing, the cells were stained with either APC-Cy7-coupled anti-mouse IgG antibodies (for TRES224, TRES6, TRES328) or APC-coupled anti-human IgG
antibodies (for R10987) and analyzed for the APC-Cy7/APC and GFP color by flow cytometry. (B) Titration of the mAb TRES224, TRES6 and R10987 to Ramos cells
carrying the indicated S proteins. As negative control we used Ramos cells without S protein (black). The mean values of three different experiments are shown.TABLE 1 | Demographic data of SARS-CoV-2 infected patients.
Patient cohort Days between diagnose
and sampling
Sex Age
C1 51 M 59
C2 94 M 53
C3 39 M 67
C4 28 M 61
C5 19 F 78
C6 8 M 74
C7 48 F 66
C8 34 F 50
C9 26 F 68
C10 46 M 65
C11 16 M 63
C12 19 M 56Median age: 64+/- 8,18 years; M, male; F, female.September 2021 | Volume 12 | Article 730766
Vesper et al. Barcoded Flow-Cytometry-Assay for SARS-CoV-2 AntibodiesFIGURE 4 | BSFA study of the serum of a vaccinated (BioNTech/Pfizer) 47-year-old female (V7) for anti-S protein IgG (upper panels) and IgA class (lower panels)
antibodies. Serum was collected 1 day before (pre) or 12 days after the first vaccination and 10 days after the second vaccination.A
B
C
FIGURE 5 | BSFA study of the sera of 12 persons vaccinated with the BioNTech/Pfizer mRNA vaccine after the primary (A) and secondary (B) vaccine doses and
of 12 patients with severe COVID-19 disease (C). Summary of the production of S protein-specific IgG (left panel) or IgA (right panel) antibodies. The sera were
diluted 1:100 and analyzed by flow cytometry for antibodies binding to Ramos cells expressing either the WT (green), the alpha variant (blue) or the beta variant (red)
S protein. Shown are normalized mean fluorescence intensity (MFI).Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 7307667
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by the anti-SARS-CoV-2 antibodies. Nonetheless, there is an
overall good correlation between the ELISA and the BSFA which
strengthens the validity of the flow cytometric assay.
We next analyzed the blood of 12 COVID-19 patients (C1-
C12) (Table 2). These sera were taken 1-12 weeks after the
SARS-CoV-2 infection and were analyzed by BSFA for S-specific
IgG or IgA antibodies (Figure 5C). All 12 persons developed S-
specific IgG class antibodies. The 12 tested persons could be
grouped into 6 high and 6 low responders with a normalized MFI
of above 5000 and below 3000, respectively. The sera of allFrontiers in Immunology | www.frontiersin.org 8infected persons also had IgG antibodies that bound to Ramos
cells expressing the alpha and beta variant S proteins, albeit with
lower binding intensity. The specific IgG antibodies always
bound Ramos cells with the alpha variant better than those
carrying the beta variant. This is in line with a study showing that
pseudoviruses carrying the S protein of the beta variant are most
resistant to neutralization by mAb and covalent plasma
antibodies (30). Similar to what we found in the analysis of
sera of persons after the second vaccination, the IgA response of
infected persons is more variable than the IgG response. Four
persons (C1, C4, C5 and C6) belonging to the IgG high
responder group also had the most robust IgA antibody
response. The IgA class antibodies in the sera of infected
persons are always bound more strongly to Ramos cells
expressing the WT than to those with a variant S protein, with
the beta variant being less well recognized than the alpha variant.Stability and Immune Recognition of
Mutated RBD
We next wanted to learn more about how a single amino acid
exchange mutation in the RBD of the S protein influences the
expression of the RBD-CD8 chimeric protein as well as its
recognition by soluble ACE2-IgG or anti-RBD antibodies. For
this, we introduced in the RBD-CD8 construct the N501Y and
the E484K point mutations characteristic for the alpha and beta
variant, respectively (Figure 6A). In addition, we introduced a
glycine to isoleucine (G496I) amino acid exchange predicted toTABLE 2 | Demographic data of vaccinated patients.
Vaccinated Cohort PV (days) SC V1 (days) SC V2 (days) Sex Age
V1 0 14 10 M 28
V2 4 10 10 M 31
V3 2 12 10 F 57
V4 0 10 10 F 52
V5 4 10 10 F 34
V6 5 12 15 F 73
V7 -1 12 10 F 47
V8 4 10 10 M 36
V9 -1 11 11 F 43
V10 5 12 15 M 79
V11 2 10 10 M 56
V12 0 11 13 M 39Median Age: 45 +/- 16,19 years; M, male; F, female; PV, Prevaccination; V1, First
Vaccination; V2, Second Vaccination; SC, Sample Collection.




FIGURE 6 | Influence of single amino acid exchange mutation in the RBD of the S protein on the expression and binding activity of the chimeric RBD-CD8 protein.
(A) Schematic drawing of the RBD-CD8 protein with either an WT (green), or an N501Y (blue), E484K (red) or G496I (grey) mutated RBD sequence. (B) Flow
cytometric analysis of the expression of the RBD-CD8 protein on Ramos cells stained with anti-mouse CD8 antibodies. (C) Titration of the ACE2-Ig binding to the
four indicated Ramos cell populations. (D) Titration of mAb TRES224, TRES6 and R10987 binding to Ramos cells carrying the indicated RBD-CD8 proteins. As
negative control we used non-transfected Ramos cells (black). The mean values of three different experiments are shown.September 2021 | Volume 12 | Article 730766
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receptor (31). Ramos cells expressing the different RBD-CD8
constructs were barcoded and first tested for the chimeric RBD-
CD8 protein expression by using anti-CD8 antibodies
(Figure 6B and Supplementary Figure 3). This experiment
showed that the N501Y and E484K mutant RBD-CD8
constructs are less expressed on Ramos cells than the WT or
G496I mutated construct. Apparently, the two former mutations
introduced some instability into the RBD of SARS-CoV-2 that is
recognized by the quality control mechanism in the endoplasmic
reticulum of Ramos B cell. We next exposed the four RBD-CD8-
expressing Ramos-null cells to different concentrations of ACE2-
Ig and analyzed them for receptor binding (Figure 6C).
Interestingly, we found that, despite its lower expression,
the N501Y mutant RBD-CD8 is bound better by ACE2-Ig than
theWT RBD-CD8 construct, whereas Ramos cells expressing the
G496I and E484K mutant RBD-CD8 constructs are less well
bound by ACE2-Ig. This finding is in line with a biolayer
interferometry study of ACE binding to RBD mutants (32).
The three RBD-specific mAb (TRES224, TRES6 and R10987)
bind to a similar extent to Ramos cells expressing the WT,
N501Y, or G496I mutant RBD-CD8 proteins, whereas those cells
expressing the E484K mutant RBD-CD8 constructs are poorly
bound by these antibodies (Figure 6D). This study suggests that
E484K is an immune escape mutation of the S protein. This
notion is supported by BSFA of the immune sera of the 12
BioNTech/Pfizer vaccinated persons of our study groupsFrontiers in Immunology | www.frontiersin.org 9(Figure 7A, B). RBD-specific IgG produced during the
secondary response of the 12 vaccinated persons binds to a
similar extent to Ramos cells carrying the WT, N501Y or G496I
RBD-CD8 but to a lesser extent to those expressing the E484K
mutant RBD-CD8 constructs. The analysis of the immune sera of
the 12 infected persons with COVID-19 reveals a similar picture
(Figure 7C). The RBD-specific IgA response showed a clear
difference between the sera from the vaccinated and those of the
SARS-CoV-2-infected group. Only 3 of the 12 BioNTech/Pfizer-
vaccinated persons developed some RBD-specific IgA antibodies
after the boost. In contrast, most infected persons showed an
RBD-specific IgA response that was relatively high in three (C1,
C5 and C6) of the infected COVID-19 patients (right panel
Figure 7). However, as most IgA antibodies are present in
mucosal tissues it is not clear how accurately blood IgA
antibody levels represent the total IgA response.DISCUSSION
We show here that retrovirally transfected Ramos-null B cells
can stably express WT or mutated variants of the S proteins and
chimeric proteins carrying only the RBD of the SARS-CoV-2
viruses. In combination with a color-coded barcoding method,
this feature allowed us to compare different S-proteins or RBD
mutants in their binding to either soluble ACE2-Ig molecule,A
B
C
FIGURE 7 | RBD binding activity of the sera of 12 persons vaccinated with the BioNTech/Pfizer mRNA vaccine after the primary (A) and secondary (B) vaccination
doses and of 12 patients with severe COVID-19 disease (C). Shown is the IgG (left panel) and IgA (right panel) antibody response of the sera diluted 1:100 and
analyzed for binding to Ramos cells expressing RBD-CD8 protein with either a WT (green), or an N501Y (blue), E484K (red) or G496I (grey) mutated RBD sequence.
Shown are normalized MFI values.September 2021 | Volume 12 | Article 730766
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vaccinated or infected persons. Ramos cells are human B cells
and are expected to express the trimeric S proteins with a
glycosylation pattern and a membrane orientation found on
viral particles emerging from human infected cells. The
transfected Ramos cells share these features with HEK293T
and Jurkat cells currently used in a coronavirus spike flow
cytometric assay (16–18). An advantage of our system is that
we use a retroviral transfection system to produce the native
form of different S proteins on the surface of Ramos cells. In
addition, retroviral vectors are efficiently and randomly
integrated into many different gene loci of a transfected cell
and thus generate a heterogenous population of transgene-
expressing cells.
Furthermore, by using an IRES-GFP vector, we can to some
extent correlate transgene with GFP expression. In this way, we
can monitor the interaction of a specific binding reagent to
Ramos cells carrying low, medium or high amounts of native S
proteins on their surface. In addition, by using the color-coded
barcoding method BSFA, we can combine up to 4 different
Ramos cells in one test tube and expose them to the same binding
reagent at a given concentration. In this way, we can directly
compare the interaction of WT and mutant S proteins with either
the soluble ACE2 receptor or specific antibodies. The BSFA can
easily be adapted to test humoral immune responses against new
SARS-CoV-2 variants and has the potential of high throughput
of antibody screening and evaluation in a time-saving fashion.
Like other RNA viruses, SARS-CoV-2 can rapidly generate
mutations during its expansion in an infected person (14). Thus,
during the corona pandemic, several SARS-CoV-2 variants have
emerged that became dominant in different world regions (33).
Successful SARS-CoV-2 variants can be classified as either fitness
and/or immune escape mutants (6). The former mutants infect
and propagate themselves more efficiently in target cells, whereas
the human immune system poorly recognizes the latter mutants.
Our BSFA study found that Ramos cells expressing the full-
length S proteins of the alpha and beta variant of SARS-CoV-2
are better bound by ACE2-Ig and by anti-RBD mAbs. This
finding suggests that the variant S proteins are either more stably
expressed on the Ramos cell than the WT S protein or resume a
conformation with a more accessable RBD. In the case of the
alpha variant, we provide direct evidence for a stronger ACE2
binding as the N501Y mutated RBD-CD8 chimera is less well
expressed yet better recognized by the ACE2-Ig reagent. This is
in line with data from a biolayer interferometry study (32). An
unexpected finding of our study was that a single point mutation
in the RBD reduces the expression of the RBD-CD8 chimera on
transfected Ramos cells. Thus, these mutations seem to have an
impact on the stability of the whole domain. In the full-length S
protein, the RBD is either in a closed or a more open
conformation, with only the open conformation able to bind to
the ACE2 target (28). Hereto, the RBD amino acid point
mutations selected by the alpha and beta variant may change
not only the stability of the RBD but also the close/open
equilibrium of the S protein and thus enable the variant virus
to attach more readily to and infect its target cell.Frontiers in Immunology | www.frontiersin.org 10With our BSFA approach, we can evaluate the quality of a
coronavirus antibody response in terms of its specificity towards
WT and variant S proteins and its target, namely epitopes within
or outside the RBD structure. As most anti-RBD antibodies block
the binding of the virus to the ACE2 entry receptor, they are
likely to have neutralizing activity (12). Furthermore, with BSFA,
we can analyze different classes of antibodies for these criteria.
The evaluation of the humoral anti-SARS-CoV-2 immunity of
the BioNTech/Pfizer-vaccinated group clearly showed an
improved IgG response directed against the S protein and the
RBD after the boost. Thus, two rounds of vaccinations are
required for the efficiency of this vaccine. The IgG response of
boosted persons was similar to that of patients with severe
COVID-19 disease. However, the 50% high responder of the
latter group developed more antibodies against the alpha variant.
The humoral immunity towards the beta variant of SARS-CoV-2
was always lower in line with the finding that beta is an immune
escape variant (30). A striking difference was seen in the IgA
response between these groups. The S protein-specific IgA
response did not improve after the second vaccination, and
only 3 of the 12 vaccinated persons produced some anti-RBD
antibodies after the boost. In contrast, 7 of the 12 COVID-19
patients had high IgA class anti-RBD antibodies titers in
their serum.
In summary, our data show that our assay is a valuable tool to
evaluate the humoral response of different immunoglobulin
classes to either the vaccine or a SARS CoV-2 infection with
either the wild-type or the mutant form of this virus.DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | Serum IgG (left) and IgA (right) response in 12 persons
before receiving the fisrt dose of the BioNTech/Pfizer mRNA vaccine. Evaluation
of the binding to Ramos cells expressing either the WT (green), the alpha variant
(blue) or the beta variant (red) S protein. (A) or Ramos cells expressing RBD-CD8
protein with either a WT (green), or an N501Y (blue), E484K (red) or G496I (grey)
mutated RBD sequences (B). Shown are normalized mean fluorescence intensity
(MFI) values.
Supplementary Figure 2 | ELISA study for IgG-class anti-S1 antibodies in the
sera of 12 persons vaccinated with the BioNTech/Pfizer mRNA vaccine and tested
before (black), after the first (orange) or the secondary vaccination (green). Shown
are the measure values related to the calibrator (measured value/calibrator).
Supplementary Figure 3 | Flow cytometric analysis of the expression of the
RBD-CD8 variants on Ramos Null cells stained with anti-mouse CD8 antibodies,
mAb TRES224, serum IgG of the individuals C1 and V7.REFERENCES
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